With an FDA complete response letter in hand, Italy’s Newron Pharmaceuticals SpA is on the hook for providing the agency with a clinical evaluation of the potential abuse liability and dependence or withdrawal effects of its Parkinson’s disease (PD) candidate, Xadago (safinamide).